Ken Griffin Equillium, Inc. Transaction History

Citadel Advisors LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.73 - $3.0 $45,765 - $188,079	-62,693 Reduced 99.51%	306 $0
Q4 2023 Feb 14, 2024	BUY	$0.48 - $0.74 $7,687 - $11,851	16,016 Added 34.09%	62,999 $45,000
Q3 2023 Nov 14, 2023	BUY	$0.72 - $0.9 $238 - $297	331 Added 0.71%	46,983 $34,000
Q2 2023 Aug 14, 2023	BUY	$0.49 - $0.79 $14,238 - $22,956	29,059 Added 165.17%	46,652 $34,000
Q1 2023 May 15, 2023	SELL	$0.56 - $1.24 $18,705 - $41,419	-33,403 Reduced 65.5%	17,593 $12,000
Q4 2022 Feb 14, 2023	BUY	$0.83 - $2.26 $42,326 - $115,250	50,996 New	50,996 $54,000
Q1 2022 May 16, 2022	SELL	$2.99 - $4.19 $46,757 - $65,523	-15,638 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$3.77 - $6.99 $17,828 - $33,055	4,729 Added 43.35%	15,638 $58,000
Q3 2021 Nov 15, 2021	SELL	$4.84 - $6.91 $50,611 - $72,257	-10,457 Reduced 48.94%	10,909 $74,000
Q1 2021 May 17, 2021	BUY	$5.03 - $10.5 $107,470 - $224,343	21,366 New	21,366 $153,000
Q2 2019 Aug 14, 2019	SELL	$5.28 - $8.2 $559,405 - $868,773	-105,948 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$5.84 - $12.02 $1,839 - $3,786	-315 Reduced 0.3%	105,948 $0
Q4 2018 Feb 14, 2019	BUY	$6.32 - $19.44 $671,582 - $2.07 Million	106,263 New	106,263 $867,000

11.3M

Ticker EQ
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,352,100
Market Cap $25.8M
Description
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which i...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.